<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Roberts, Ian</style></author><author><style face="normal" font="default" size="100%">Mann, Kenneth</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Management of Posttraumatic Bleeding and Trauma-Induced Coagulopathy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-10 10:58:07</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">Data from the CRASH-2 trial showed that tranexamic acid significantly reduced mortality in trauma patients, but no harm was detected. It is most effective when tranexamic acid is administered within 3 hours of the initial traumatic event. The TACTIC collaboration is currently conducting multiple preclinical and clinical studies to better manage posttraumatic hemorrhage.</style></abstract><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>